Dermatología, Hospital Universitario Príncipe de Asturias, España.
Dermatología, Hospital Universitario Príncipe de Asturias.
Rev Esp Enferm Dig. 2020 Dec;112(12):960-961. doi: 10.17235/reed.2020.7138/2020.
We present the case of a patient with a debut of reactive perforating collagenosis associated with the use of Sorafenib for stage IV hepatocarcinoma, very successfully controlled with local corticotherapy and systemic antihistamines. This is an extremely rare side effect associated with this treatment, as only another eleven cases of acquired perforating dermatoses associated with Sorafenib or other multi-kinase inhibitors have been found in the medical literature. Given the unusual nature of this presentation, high clinical suspicion and a correct histopathological study are indispensable for its correct filiation and treatment.
我们报告了一例初发的反应性穿透性胶原病患者，该患者因 IV 期肝癌使用索拉非尼治疗，通过局部皮质激素治疗和全身抗组胺治疗得到了非常好的控制。这是与该治疗相关的一种极其罕见的副作用，因为在医学文献中仅发现了另外 11 例与索拉非尼或其他多激酶抑制剂相关的获得性穿透性皮肤病。鉴于这种表现形式的罕见性，高临床怀疑和正确的组织病理学研究对于正确的家族史和治疗是必不可少的。
